These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12929622)

  • 1. Two Italian kindreds carrying the Arg136-->Ser mutation of the Apo E gene: development of premature and severe atherosclerosis in the presence of epsilon 2 as second allele.
    Rolleri M; Vivona N; Emmanuele G; Cefalù AB; Pisciotta L; Guido V; Noto D; Fiore B; Barbagallo CM; Notarbartolo A; Travali S; Bertolini S; Averna MR
    Nutr Metab Cardiovasc Dis; 2003 Apr; 13(2):93-9. PubMed ID: 12929622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies.
    Pocovi M; Cenarro A; Civeira F; Myers RH; Casao E; Esteban M; Ordovas JM
    Atherosclerosis; 1996 Apr; 122(1):33-46. PubMed ID: 8724110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype.
    Feussner G; Funke H; Weng W; Assmann G; Lackner KJ; Ziegler R
    Eur J Clin Invest; 1992 Sep; 22(9):599-608. PubMed ID: 1360898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apo E variants in patients with type III hyperlipoproteinemia.
    Civeira F; Pocoví M; Cenarro A; Casao E; Vilella E; Joven J; González J; Garcia-Otín AL; Ordovás JM
    Atherosclerosis; 1996 Dec; 127(2):273-82. PubMed ID: 9125318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
    Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
    Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
    J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
    Lin HP; Kao JT
    Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compound heterozygotes for a novel mutation, apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with severe type III hyperlipoproteinemia and familial hypercholesterolemia.
    Sakuma N; Hibino T; Saeki T; Nagata T; Sato T; Okuda N; Matsunaga A; Sasaki J
    J Atheroscler Thromb; 2014; 21(9):983-8. PubMed ID: 24953047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.
    Wardell MR; Brennan SO; Janus ED; Fraser R; Carrell RW
    J Clin Invest; 1987 Aug; 80(2):483-90. PubMed ID: 3038959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial dysbetalipoproteinemia in three patients with apoE 2*(Arg136-->Cys) gene variant.
    Vrablík M; Horínek A; Ceska R; Stulc T; Kvasnicka T
    Physiol Res; 2003; 52(5):647-50. PubMed ID: 14535841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping.
    Walden CC; Huff MW; Leiter LA; Connelly PW; Hegele RA
    J Clin Endocrinol Metab; 1994 Mar; 78(3):699-704. PubMed ID: 7907341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg136-->Cys) variant.
    Feussner G; Albanese M; Valencia A
    Atherosclerosis; 1996 Oct; 126(2):177-84. PubMed ID: 8902143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable expression of hypercholesterolemia in Apolipoprotein E2* (Arg136 --> Cys) heterozygotes.
    Hubácek JA; Pitha J; Stávek P; Schmitz G; Poledne R
    Physiol Res; 2000; 49(3):307-14. PubMed ID: 11043917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and consequences of apolipoprotein-epsilon(3Groningen): a G-insertion in codon 95/96 that is predicted to cause a premature stop codon.
    Dijck-Brouwer DA; van Doormaal JJ; Kema IP; Brugman AM; Kingma AW; Muskiet FA
    Ann Clin Biochem; 2005 Jul; 42(Pt 4):264-8. PubMed ID: 15989726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan.
    Kobori S; Nakamura N; Uzawa H; Shichiri M
    Atherosclerosis; 1988 Jan; 69(1):81-8. PubMed ID: 3355609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a new apolipoprotein E variant (E2 Arg142-->Leu) in type III hyperlipidemia.
    Richard P; de Zulueta MP; Beucler I; De Gennes JL; Cassaigne A; Iron A
    Atherosclerosis; 1995 Jan; 112(1):19-28. PubMed ID: 7772063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compound heterozygote for both rare apolipoprotein E1 (Gly127-->Asp, Arg158-->Cys) and E3(Cys112-->Arg, Arg251-->Gly) alleles in a multigeneration pedigree with hyperlipoproteinaemia.
    Richard P; Beucler I; Pascual De Zulueta M; Biteau N; De Gennes JL; Iron A
    Clin Sci (Lond); 1997 Jul; 93(1):89-95. PubMed ID: 9279208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E polymorphism and atherosclerosis.
    Davignon J; Gregg RE; Sing CF
    Arteriosclerosis; 1988; 8(1):1-21. PubMed ID: 3277611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E polymorphism in health and disease.
    Utermann G
    Am Heart J; 1987 Feb; 113(2 Pt 2):433-40. PubMed ID: 3544759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
    Weisgraber KH; Newhouse YM; Taylor JM; Tuan B; Nestruck AC; Davignon J; Mahley RW
    Arteriosclerosis; 1989; 9(1):50-7. PubMed ID: 2912421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.